INTRODUCTION
Matrix metalloproteinases (MMPs) are considered to play central roles in the degradation of connective tissues (Woessner, 1991; Birkedal-Hansen et al., 1993) . Three main MMPs secreted from rheumatoid synovial cells and other connective-tissue cells have been isolated and characterized for their abilities to degrade extracellular-matrix components. MMP-1 (interstitial collagenase) attacks collagen types I, II, III, VII and X (Seltzer et al., 1989; Schmid et al., 1986) ; in addition, it is capable of degrading casein (Windsor et al., 1991) and cartilage proteoglycan (Hughes et al., 1991) . MMP-2 (gelatinase A) readily degrades gelatins, but also has activity on collagen types IV, V and VII, elastin and proteoglycan (Murphy et al., 1985 Seltzer et al., 1989; Okada et al., 1990; Senior et al., 1991) . has a wide spectrum of substrates that include proteoglycans, laminin, fibronectin and collagens type IV and IX (Okada et al., 1986 . All three enzymes are secreted from the cell as precursor forms which require activation. The activation of proMMP-l can be initiated by trypsin-like serine proteinases to generate partially active MMP-1 intermediates, but the action of MMP-3 is crucial for the subsequent full activation of MMP-1 (Murphy et al., 1987; Ito and Nagase, 1988; He et al., 1989; Suzuki et al., 1990) . The activation of proMMP-3 can be achieved by various serine proteinases such as trypsin, chymotrypsin, human neutrophil elastase, plasmin, and plasma kallikrein (Okada et al., 1988) by stepwise processing of the propeptide . All these zymogens are also activated in vitro by exposure to organomercurials (Woessner, 1991) . However, the mechanism(s) of metalloproteinase activation in vivo remains uncertain. It is likely that these activator enzymes may 52 kDa proMMP-1 by converting it into a 41 kDa protein and generating the new N-termini, namely Gln80 and Val82. The collagenolytic activity which resulted from this cleavage was only 35 % of the full activity, but this could not be augmented by subsequent treatment with MMP-3, the latter being a crucial enzyme for the generation of the fully active MMP-1 with Phe81 at the N-terminus, in conjunction with other serine proteinases. Thus RMCP II activates proMMP-l via a mechanism different from that reported for the stepwise processing by combinations of other trypsin-like enzymes and MMP-3. ProMMP-2 (progelatinase A) was not activated by either RMCP I or RMCP II, despite processing to smaller products.
arise from the connective-tissue cell itself or from other cell types such as granulocytes and macrophages.
Several reports have noted the association of mast cells with areas of connective-tissue degradation, especially at sites of tumour invasion in breast carcinoma and melanoma (Hartveit et al., 1984; Dabbous et al., 1986) and at sites of cartilage erosion in rheumatoid arthritis . Mast-cell proteinase extracts were reported to activate proMMP-l (Birkedal-Hansen et al., 1976; Dabbous et al., 1986) , and recent studies have shown that mast-cell tryptase generates collagenase activity indirectly through its ability to activate proMMP-3 (Gruber et al., 1989) . In addition to tryptase, mast cells may contain chymases, serine proteinases which are chymotrypsin-like in substrate specificity and molecular mass (Katunuma et al., 1975; Woodbury and Neurath, 1978; . These enzymes have been characterized in rat and designated as rat mast-cell proteinase I (RMCP I) and II (RMCP II) (Woodbury and Neurath, 1978; . RMCP I is the major proteinase component of connectivetissue mast cells, whereas RMCP II is derived from mucosal mast cells (Woodbury et al., 1978a,b) . Similar enzymes are present in human mast cells, and the content of tryptase relative to chymase is one of the main features of mast-cell heterogeneity, which is recognized not only between species, but also between different tissues (Irani et al., 1986; Weidner and Austin, 1993 
Enzymes
ProMMP-1 (interstitial procollagenase), proMMP-2 (progelatinase A) and proMMP-3 (stromelysin 1) were purified from culture medium of human rheumatoid synovial fibroblasts stimulated with rabbit macrophage-conditioned medium as described previously Okada et al., 1990; Ito and Nagase, 1988) . The final products were homogeneous on SDS/PAGE. RMCP I was purified from mast cells obtained from rat peritoneal lavage and RMCP II from the small intestine of rats hyperimmunized with the nematode Nippostrongylus brasiliensis as described previously . The final products were homogeneous on SDS/PAGE. However, since a very small amount of trypsin-like activity was detected in the RMCP II preparation this was eliminated by treatment with 100 ,uM Tos-Lys-CH2Cl at 23°C for 1 h prior to use in proMMP activation studies.
Enzyme assays
Collagenolytic activity was measured by the diffuse fibril method of Cawston and Barrett (1979) Western-blot analysis Samples resolved by SDS/PAGE (7.5 % total acrylamide) under reducing conditions were electrotransferred on to nitrocellulose filters as described by Burnett (1981) . Non-specific binding of IgG was blocked by 22 % (w/v) fat-free-milk solution. The filters were then allowed to react with sheep anti-(human MMP-3) serum (1:3000 dilution) at room temperature for 16 h. After extensive washing, anti-MMP-3 antibodies bound to the antigens were allowed to form a complex with peroxidase-conjugated goat anti-(sheep IgG) IgG for 2 h at room temperature and the protein bands were subsequently revealed using diaminobenzidine tetrahydrochloride and H202 (Towbin et al., 1979) . 
N-terminal sequence analysis
Automatic sequence analyses were performed with an Applied Biosystems 477A pulse liquid-phase sequencer with 'on line' 120A phenylthiohydantoin-amino acid analysis. To determine the N-terminal sequence, RMCP II-treated proMMP-1 or proMMP-3 was separated by SDS/PAGE (7.5% total polyacrylamide) under reducing conditions and transferred from the polyacrylamide gel to poly(vinylidene difluoride) membrane according to the procedure described by Matsudaira (1987) . The proteins transferred to the poly(vinylidene difluoride) membrane were located by staining with Coomassie Brilliant Blue R250, and the bands of interest were excised, placed on a Polybrenetreated glass filter and sequenced.
RESULTS

Activation of ProMMP-3 by RMCPs I and 11
Incubation of proMMP-3 with RMCP I at 37°C resulted in concentration-and time-dependent activation: the precursor was fully activated by 5 ,ug/ml of RMCP I within 1 h. This activation rate was about three times higher than that observed with 1.5 mM APMA at 37°C (Figure la) . Incubation with RMCP II at 37°C also activated in a concentration-and time-dependent manner, but the rate of activation by RMCP II was lower than that by RMCP I (Figure lb) . The specific activity of the fully activated MMP-3 was 845 units/mg. SDS/PAGE analysis of proMMP-3 activated by RMCP I or RMCP II showed that proMMP-3 was converted first into the active form of 45 kDa, and then converted into a 28 kDa polypeptide on longer incubation (Figure 2 ), a response typically seen after an incubation with APMA . Both the 45 kDa and the 28 kDa species were previously shown to have indistinguishable proteolytic activity (Okada et al., 1986 Figure 2 Processing of proMMP-3 by RMCPs I and 11
ProMMP-3 (5 ,ug/ml) was treated with RMCP (5 ,ug/ml) or RMCP 11 (5 ,ug/ml) at 37°C for various periods of time. The reactions were terminated with 2 mM DFP and 20 mM EDTA and the samples analysed by SDS/7.5%-PAGE under reducing conditions by silver staining (lanes 1-6) or Western blot (lanes 7 and 8). Lane 1, proMMP-3 alone; lanes 24, proMMP-3 incubated with RMCP at 37 OC for 30 min, 1, 2, 4 and 24 h respectively; lanes 7 and 8, proMMP-3 treated with RMCP II at 37 OC for 4 and 24 h respectively. was Phe-Arg-Thr-Phe-Pro, identical with the sequence produced by human neutrophil elastase or APMA ). These results suggest that both RMCPs I and II follow a typical stepwise activation of proMMP-3 as described for other proteinases (Nagase et al., 1991) .
Activation of proMMP-1 by RMCP 11 Incubation of proMMP-I with RMCP 1 (1-5 ug/ml) at 37°C up to 72 h did not exhibit collagenolytic activity. However, when proMMP-1 was incubated with RMCP II the activity against type I collagen increased in a time-dependent manner, but the maximal specific activity of MMP-l was limited to about 35 % of the fully active MMP-1 (9450 compared with 27000 units/mg). Since MMP-3 is required for full activation of proMMP-1 , the proMMP-I treated with RMCP II was allowed to react further with MMP-3. However, the specific activity of MMP-1 did not increase, whereas proMMP-1 treated with plasmin or APMA was fully activated by subsequent incubation with MMP-3 (see Table 1 ). SDS/PAGE analysis showed that proMMP-1 was converted into a 41 kDa protein by RMCP II (Figure 3 ). Further treatment of this 41 kDa MMP-1 with MMP-3 did not cause any changes in molecular mass (Figure 3) . Similarly, proMMP-1 co-treated with RMCP II and MMP-3 did not show any significant changes in the specific activity and molecular mass (results not shown). These results differ with those obtained after plasmin treatment of proMMP-1; plasmin initially processed the 52 kDa proMMP-1 to a 46 kDa protein, then to a 43 kDa MMP-1 which exhibited 14°h of the full activity (Table 1 ). The 43 kDa form was further converted into the fully active 41 kDa MMP-1 by the specific action of MMP-3 (Table I and ProMMP-1 (5 ,ug/ml) was allowed to react with RMCP 11 (5 jIg/ml) or plasmin (10 ,ug/ml) at 37°C for 24 h or 72 h. After terminating RMCP II and plasmin activities with 2 mM DFP, the samples were further incubated at 37 OC for 1 h with or without MMP-3 (4 ,Ig/ml). After incubation the enzymic activities of MMP-1 and MMP-3 were terminated with 20 mM EDTA and protein analysed by SDS/PAGE (7.5% acrylamide) under reducing conditions by staining with silver. The N-terminal sequence of MMP-1 generated by RMCP II was determined and aligned with the amino acid sequence deduced from cDNA sequencing (Goldberg et al., 1986) . MMP-1 species generated by plasma kallikrein (PKK), plasmin (PL), APMA, and MMP-3 were taken from Suzuki et al. (1990) , and the initial trypsin cleavage sites from Grant et al. (1987) . MMP-1 activities are dependent on the presence of the reagents indicated in square brackets. The molecular masses of various intermediates generated during the activation processes are shown in parentheses.
gelatinolytic activity of MMP-2 as described previously (Okada et al., 1990) . Such a molecular species was not observed after incubation with RMCP I or RMCP II.
DISCUSSION
MMPs secreted from connective-tissue cells are key enzymes in degradation of extracellular matrix under both physiological and pathological conditions [see Woessner (1991) , Matrisian (1992) and Birkedal-Hansen et al. (1993) for reviews]. The production of proMMP-1 and proMMP-3 from mesenchymal cells such as fibroblasts and chondrocytes is greatly enhanced by inflammatory cytokines and other stimulatory factors (see Woessner, 1991; Birkedal-Hansen et al., 1993) , but once secreted these zymogens require local activation to express their enzymic properties.
Observations of mast-cell activation associated with connectivetissue degradation Dabbous et al., 1986) have suggested that mast-cell proteinases may contribute to matrix breakdown, possibly by their potential to activate proMMPs at these tissue sites. In the present study we have examined two closely related RMCPs, I and II, for their abilities to activate proMMPs -1, -2 and -3, and have demonstrated that both enzymes activate proMMP-3, but only RMCP II participates in proMMP-1 activation. Neither proteinase activated proMMP-2. Our previous studies showed that a large number of proteinases, regardless of their specificities, could activate proMMP-3, but activation of proMMP-1 was restricted to trypsin-like enzymes (Nagase et al., 1991) . This is indicated by sequences around the 'bait' region located in the middle of MMP propeptides where the initial proteolytic cleavages take place. In proMMP-3 this region was identified in the stretch Phe34-Val-Arg-Arg-Lys-Asp39 that accommodates activating cleavages by a number of proteinases . Since chymotrypsin cleaves the Phe34-Val35 bond, it was conceivable that both RMCPs I and II would attack this bond and thereby trigger the stepwise activation of proMMP-3. Indeed, the N-terminal sequence analysis of the final 45 kDa MMP-3 generated with RMCP II revealed Phe83 as its N-terminus, as predicted from the previous studies with other proteinases .
The activation of proMMP-1 by the chymotrypsin-like proteinase RMCP II was unexpected, since previous studies suggested that the initial cleavage of the 'bait region' of proMMP-1 (Glu33-Lys-Arg-Arg-Asn37) is required for activation. This generation of intermediate forms are further processed to the 43 kDa or the 41 kDa form by autolysis, or to the fully active 41 kDa collagenase by specific cleavage of the Gln80-Phe8'l bond by MMP-3 . The lack of aromatic residues in this region suggests that RMCP II may directly attack the Ala79-Gln80 and the Phe81-Val82 bonds. Indeed, intermediate forms (43-47 kDa) of MMP-l were not observed with RMCP II even after incubation at 0°C for 48 h, conditions under which autolytic processing of MMP-1 was largely suppressed (results not shown). Thus the mode of proMMP-l activation by RMCP II appears to by-pass the stepwise processing of the propeptide demonstrated for other activating proteinases. While this paper was under review, Saarinen et al. (1994) reported that human mast-cell chymase also directly activates human proMMP-1 by cleaving the Leu83-Thr84 bond, and this activation process was markedly enhanced by heparin. However, RMCP II activity is not dependent on the presence of heparin. The different cleavage sites in proMMP-1 produced by human chymase (Saarinen et al., 1994) and RMCP II may result from subtle differences in subsite requirements of the two enzymes.
Incubation of proMMP-1 with RMCP II resulted in about 35 0 of the full collagenolytic activity, but the activity did not increase after incubation with This observation is analogous to that of MMP-1 generated by autolytic cleavage of the Phe81-Val82 and the Val82-Leu83 bonds at the junction of the propeptide and catalytic domain of MMP-1 ).
Activation of matrix metalloproteinases by mast-cell proteinases Autolytically generated MMP-1 with N-terminal Val82 or Leu83 expressed only about 40 % of the maximal collagenolytic activity. These observations have led us to postulate that N-terminal Phe81 plays a critical role in governing the level of collagenolytic activity. The importance of Phe8" of the N-terminus for the full collagenolytic activity has been emphasized by the recent crystallographic studies of the catalytic domain of MMP-8 (neutrophil collagenase) by Bode and colleagues Reinemer et al., 1994) . Their studies demonstrated structural stability by forming a salt bridge between the ammonium group of the N-terminal Phe79 (corresponding to Phe81 in MMP-1) and the side-chain carboxylate group of Asp232 . Without Phe79, the N-terminal hexapeptide Met80-Leu-Thr-Pro-Gly-Asn85 was disordered . It is postulated that a small structural (motional) difference may lead to different stabilization of the active site and of the transition state, or the mobile N-terminal segment may interfere with substrate binding to the active site . MMP-1 generated by RMCP II has either one extra residue (Gln80) or lacks Phe8l. Such molecules are unlikely to form a stable N-terminal salt bridge with the carboxylate group of Asp232. Once these molecules are generated by RMCP II cleavage, MMP-3 can no longer participate in MMP-1 activation, as MMP-3 requires a stretch of at least four amino acids on the Nterminal side of the scissile bond for effective hydrolysis (Niedzwieki et al., 1992) .
To date no proteinases have been shown to activate purified proMMP-2, although in most cases it becomes degraded (Okada et al., 1990 ). The present study adds two more enzymes to this list, namely RMCPs I and II. Keski-Oja et al. (1992) reported the processing of the 72 kDa proMMP-2 to a 62 kDa by urokinase, but no gelatinolytic activity was detected with the 62 kDa species unless it was treated with SDS. The inability of many endopeptidases to activate proMMP-2 may be explained by the unique sequence of the propeptide which corresponds to the 'bait' regions of the other proMMPs (Nagase et al., 1991) . However, studies by Brown et al. (1990) and Overall and Sodek (1990) demonstrated that phorbol myristate acetate-or concanavalin A-treated fibroblasts and some tumour-cell lines express a cell surface-bound 'activator' of proMMP-2. This may be a key endogenous activator for proMMP-2, but the biochemical properties are not clear and have yet to be characterized.
Variation in proteinase content is a major feature of mast-cell heterogeneity in rat and man (Irani et al., 1986; Newlands et al., 1987) . In the rat RMCP I is found in 'connective tissue-type' mast cells of skin, lung and muscle, whereas RMCP II is located mainly in the mucosal-type mast cells of the gut and airways (Gibson and Miller, 1986) . In humans, tryptase is the dominant enzyme of most mast cells found in mucosal tissue of the gut, lung and airway, but mast cells containing both tryptase and the chymotrypsin-like enzymes (chymase) are found in all tissues, especially in skin and intestinal submucosa (Irani et al., 1986; Weidner and Austen, 1993) . Together with the recent realization that mast cells may express a vareity of cytokines, including tumour necrosis factor a and interleukin 1 (see Gordon et al., 1990; Galli et al., 1991) , it seems plausible that mast cells may contribute to the local regulation of collagen and matrix catabolism. Such a view was expressed by Birkedal-Hansen et al. (1976) on the basis of procollagenase activation by mast-cell proteinases. More recent evidence in support of this theory includes the observation of mast-cell activation/degranulation in association with areas of connective-tissue lysis, such as cartilage erosion sites in rheumatoid arthritis and at the tumour periphery of rat mammary adenocarcinoma and released by mast cells have been shown to stimulate the production of proMMP-1 by fibroblasts and tumour cells in vitro (Yoffe et al., 1984; Dabbous et al., 1986) , and to stimulate monocyte-macrophages to produce increased amounts of interleukin 1, a cytokine known to stimulate MMP production by connective-tissue cells (Yoffe et al., 1985) . Thus it would appear that mast-cell activation in vivo may contribute to localized matrix degradation, both by the stimulation of MMP production by resident connective-tissue cells and by the subsequent activation of released precursors by mast-cell proteinases.
RMCP I and RMCP II are very similar in amino acid sequence, three-dimensional structure and specificity towards synthetic substrates (Le Trong et al., 1987; Woodbury et al., 1989) . However, despite similarities with chymotrypsin and cathepsin G, the physiological roles of the two RMCPs remain uncertain, although it has been assumed they probably have similar functions (Woodbury et al., 1989) . The report that RMCP I remains associated with secreted granule heparin whereas RMCP II freely dissociates from released granules (Schwartz et al., 1981) suggests a different extracellular distribution for the two enzymes following mast-cell activation.
Our studies have shown that in vitro both RMCP I and II can activate proMMP-3, only RMCP II was found to activate proMMP-1, and neither enzyme was capable of activating proMMP-2. These different actions on specific proMMPs support the concept that mast-cell subtypes with different proteinase compositions may assume tissue-specific regulatory roles for MMP-mediated degradation of matrix components. However, the relatively slow activation of proMMP-1 by RMCP II, and the reduced collagenolytic activity resulting from the unique cleavage site, may provide an active collagenase species with specific properties for matrix degradation in vivo. As yet it remains to be determined which active forms of MMP-1 are generated in vivo, this probably being related to the cellular composition and type of matrix remodelling in various tissue locations.
